Chemomab Therapeutics Ltd.

NasdaqCM:CMMB Stock Report

Market Cap: US$12.5m

Chemomab Therapeutics Management

Management criteria checks 3/4

Chemomab Therapeutics' CEO is Adi George, appointed in Jan 2011, has a tenure of 15.5 years. total yearly compensation is $800.00K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 1.23% of the company’s shares, worth $154.47K. The average tenure of the management team and the board of directors is 2.8 years and 5.3 years respectively.

Key information

Adi George

Chief executive officer

US$800.0k

Total compensation

CEO salary percentage100.00%
CEO tenure15.5yrs
CEO ownership1.2%
Management average tenure2.8yrs
Board average tenure5.3yrs

Recent management updates

Recent updates

Analysis Article • Jan 10

Will Chemomab Therapeutics (NASDAQ:CMMB) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Sep 19

Chemomab Therapeutics (NASDAQ:CMMB) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Aug 12

Chemomab Therapeutics - ADR GAAP EPS of -$0.027

Chemomab Therapeutics - ADR press release (NASDAQ:CMMB): Q2 GAAP EPS of -$0.027. Cash, cash equivalents and bank deposits were $51.8 million as of June 30, 2022, compared to $57.5 million at March 31, 2022.
Seeking Alpha • Dec 03

Chemomab Therapeutics: Pioneering Anti-CCL24 MAb For Fibrotic Diseases

Chemomab Therapeutics is advancing a first-in-class anti-CCL24 mAb targeting PSC, SSc, and NASH. Lead candidate CM-101 has orphan drug designation by both the FDA and the EMA in its primary indications of PSC and SSc. The company has a cash runway through mid-2023 and has multiple upcoming catalysts.

CEO Compensation Analysis

How has Adi George's remuneration changed compared to Chemomab Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$7m

Dec 31 2025US$800kUS$800k

-US$9m

Sep 30 2025n/an/a

-US$10m

Jun 30 2025n/an/a

-US$12m

Mar 31 2025n/an/a

-US$13m

Dec 31 2024US$700kUS$700k

-US$14m

Sep 30 2024n/an/a

-US$14m

Jun 30 2024n/an/a

-US$15m

Mar 31 2024n/an/a

-US$19m

Dec 31 2023US$330kUS$330k

-US$24m

Sep 30 2023n/an/a

-US$29m

Jun 30 2023n/an/a

-US$33m

Mar 31 2023n/an/a

-US$31m

Dec 31 2022US$435kUS$298k

-US$28m

Sep 30 2022n/an/a

-US$24m

Jun 30 2022n/an/a

-US$19m

Mar 31 2022n/an/a

-US$16m

Dec 31 2021US$488kUS$249k

-US$12m

Sep 30 2021n/an/a

-US$9m

Jun 30 2021n/an/a

-US$8m

Mar 31 2021n/an/a

-US$6m

Dec 31 2020US$325kUS$229k

-US$6m

Compensation vs Market: Adi's total compensation ($USD800.00K) is about average for companies of similar size in the US market ($USD658.93K).

Compensation vs Earnings: Adi's compensation has increased whilst the company is unprofitable.

CEO

Adi George (44 yo)

15.5yrs
Tenure
US$800,000
Compensation

Dr. Adi Mor George, Ph.D. serves as Chief Executive Officer of Chemomab Therapeutics Ltd. since June 01, 2023. She is the Co-Founder of Chemomab Therapeutics Ltd.and has been its Chief Scientific Officer...

Leadership Team

NamePositionTenureCompensationOwnership
Adi George
Co-Founder15.5yrsUS$800.00k1.23%
$ 154.5k
Sigal Fattal
Chief Financial Officer3.1yrsUS$600.00k0.20%
$ 25.2k
John Lawler
Chief Development Officer2.5yrsUS$728.50k0.051%
$ 6.4k
Barbara Lindheim
Consulting Vice President of Investor & Public Relationsno datano datano data
David Weiner
Interim Chief Medical Officer1.3yrsno datano data
2.8yrs
Average Tenure
58yo
Average Age

Experienced Management: CMMB's management team is considered experienced (2.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Adi George
Co-Founder5.3yrsUS$800.00k1.23%
$ 154.5k
Neil Cohen
Independent Director6.3yrsUS$123.00k0.49%
$ 61.4k
Gwen A. Melincoff
Independent Directorless than a yearno datano data
Nissim Darvish
Independent Chairman5.3yrsUS$123.00k0.0042%
$ 522.4
Alan Moses
Independent Director5.3yrsUS$119.00k0%
$ 0
Scott L. Friedman
Member of Scientific Advisory Boardno datano datano data
Massimo Pinzani
Member of Scientific Advisory Boardno datano datano data
Arun Sanyal
Member of Scientific Advisory Boardno datano datano data
Marco Matucci-Cerinic
Member of Scientific Advisory Boardno datano datano data
Dinesh Khanna
Member of Scientific Advisory Boardno datano datano data
Francesco Del Galdo
Member of Scientific Advisory Boardno datano datano data
Jacob George
Member of Scientific Advisory Boardno datano datano data
5.3yrs
Average Tenure
62yo
Average Age

Experienced Board: CMMB's board of directors are considered experienced (5.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/13 08:25
End of Day Share Price 2026/07/10 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Chemomab Therapeutics Ltd. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason McCarthyMaxim Group
Michael OkunewitchMaxim Group
Jeffrey JonesOppenheimer & Co. Inc.